Available Now and Fully Covered by Medicare
A clear path forward: the latest innovation in kidney transplant surveillance can drive better outcomes for your patients
AlloSure is the first and only non-invasive test that assesses organ health by directly measuring allograft injury. AlloSure can accurately determine active rejection, enabling better management of your kidney transplant patients.
AlloSure is a clinically and analytically validated, non-invasive blood test that measures donor-derived cell-free DNA (dd-cfDNA), an indicator of kidney injury.
Cell-free DNA: a clear biomarker
Cell-Free DNA (cfDNA) is fragmented DNA in the bloodstream that originates from cells undergoing cell injury and death.
When graft injury occurs, donor-derived cell-free DNA (dd-cfDNA) increases in the blood.
AlloSure accurately measures dd-cfDNA and is a powerful, non-invasive tool for kidney transplant surveillance.
Put your patients on a clear path forward with AlloSure
- Measures donor-derived cfDNA, a direct indicator of kidney injury
- Clinically and analytically validated
- More accurate than serum creatinine in diagnosis of active rejection
- Does not require donor or recipient genotyping
- Appropriate for a wide array of patients who are 2 weeks or more post transplant
- Covered by Medicare
1 Grskovic M, Hiller DJ, Eubank LA, et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn. 2016;18:890.
2 Bloom RD., Bromberg JS, Poggio E, et al. Cell-free DNA and active rejection in kidney allografts. J Am SocNephrol. 2017; 28:2221.
3 Bromberg JS, Brennan DC, Poggio E, et al. Biological variation of donor-derived cell-free DNA in renal transplant recipients: clinical implications. J Appl Lab Med. 2017; 2:309.